Thierry Gil

Service(s) : Clinique d'oncologie médicale

thierry.gil [at] hubruxelles.be

Publications

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.

Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ
Année : 2022
Journal : Prostate Cancer Prostatic Dis

(68)Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.

Auteurs : Shagera QA, Artigas C, Karfis I, Critchi G, Chanza NM, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P
Année : 2022
Journal : J Nucl Med

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.

Auteurs : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M
Année : 2022
Journal : Diagnostics (Basel)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.

Auteurs : Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG
Année : 2022
Journal : Oncologist

Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis.

Auteurs : Dumont L, Salaroli A, Dal Lago L, Gil T, Pepersack T
Année : 2021
Journal : Eur J Case Rep Intern Med

Plus de publications »

Thierry Gil

Languages

Contact